Evidence map›Paper›PMID 33409256›Full record

ArticleJournal of cancer prevention2020

Interaction between Peptidyl-prolyl

Soma Saeidi, Sihyung Joo, Su-Jung Kim, Achanta Sri Venkata Jagadeesh, Young-Joon Surh

Abstract read
In one paragraph

Article in Journal of cancer prevention, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Soma SaeidiDepartment of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea.ORCID https://orcid.org/0000-0002-4943-5596
Sihyung JooCollege of Pharmacy, Seoul National University, Seoul, Korea.ORCID https://orcid.org/0000-0003-0195-1820
Su-Jung KimTumor Microenvironment Global Core Research Center, College of Pharmacy, Seoul National University, Seoul, Korea.ORCID https://orcid.org/0000-0002-3636-0644
Achanta Sri Venkata JagadeeshTumor Microenvironment Global Core Research Center, College of Pharmacy, Seoul National University, Seoul, Korea.ORCID https://orcid.org/0000-0002-6073-7202
Young-Joon SurhDepartment of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea.ORCID https://orcid.org/0000-0001-8310-1795

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aberrant activation of Ras has been implicated in aggressiveness of breast cancer. Among Ras isoforms (H-, K-, and N-), H-Ras has been known to be primarily responsible for invasion and metastasis of breast cancer cells. Phosphorylation of serine (Ser) or threonine (Thr) is a key regulatory mechanism responsible for controlling activities and functions of various proteins involved in intracellular signal transduction. Peptidyl-prolyl

Indexed as

Breast neoplasmDrug resistanceH-RasPeptidyl-prolyl cis-trans isomerase NIMA-interacting 1

Identifiers

PMID33409256
PMCPMC7783236

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.